Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1/2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Gastrointestinal 1

Conditions

Multiple Myeloma 2Metastatic Pancreatic Adenocarcinoma 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
BKT140 × Clear all
NCT07101445 2026-02-10

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Emory University

Phase 4 Recruiting
94 enrolled
Plasma cell

Multiple Myeloma

NCT02907099 2025-02-19

Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
20 enrolled 12 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT01010880 2011-06-10

Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients

Biokine Therapeutics Ltd

Phase 1/2 Completed
16 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡